{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:52:03Z","timestamp":1791503523827,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:07:04Z","timestamp":1791432424000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision before incision: neoadjuvant tumor-agnostic therapies"],"prefix":"10.1016","author":[{"given":"Juliana","family":"Beal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Sicklick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.09.001_bb0005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41571-020-0384-0","article-title":"Histology-agnostic drug development \u2013 considering issues beyond the tissue","volume":"17","author":"Pestana","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0015","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.001_bb0020","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2026.09.001_bb0025","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/s41467-025-57941-0","article-title":"Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals","volume":"16","author":"Sledge","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.001_bb0030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","article-title":"Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives","volume":"18","author":"Lee","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.trecan.2026.09.001_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0055","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003854","article-title":"Intratumor heterogeneity: seeing the wood for the trees","volume":"4","author":"Yap","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0085","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II\u2013IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0095","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0100","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0105","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.soc.2023.12.002","article-title":"Targeted therapies, biologics, and immunotherapy in the neoadjuvant and adjuvant settings: perioperative risks","volume":"33","author":"Nishizaki","year":"2024","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.trecan.2026.09.001_bb0115","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0120","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.09.001_bb0130","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-23-0090","article-title":"Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications","volume":"29","author":"Gouda","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.001_bb0135","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.31701","article-title":"The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas","volume":"124","author":"DuBois","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2026.09.001_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103006","article-title":"Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)","volume":"9","author":"Orbach","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.09.001_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers12113246","article-title":"Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis","volume":"12","author":"Italiano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.09.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0179","article-title":"Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report","volume":"12","author":"Dam\u00e1sio","year":"2023","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.trecan.2026.09.001_bb0155","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1178313","article-title":"Case report: complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer","volume":"13","author":"Goldman","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.107140","article-title":"Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: two case reports","volume":"161","author":"Yu","year":"2025","journal-title":"Oral Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0170","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1007\/s00432-022-04496-y","article-title":"Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma","volume":"149","author":"Schrenk","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnci\/djad232","article-title":"Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach","volume":"116","author":"Grynberg","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2026.09.001_bb0180","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.trecan.2026.09.001_bb0185","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.09.001_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0200","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0220","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P02-02","article-title":"Abstract P02-02: first results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors","volume":"20","author":"Goyal","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.09.001_bb0230","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.09.001_bb0235","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41698-025-01044-y","article-title":"Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors","volume":"9","author":"Xiang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0240","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0245","series-title":"IASLC\/ASCO North America Conference on Lung Cancer","article-title":"Efficacy and safety of zenocutuzumab in treatment-naive advanced NRG1 fusion-positive NSCLC: updated results from the phase II eNRGy trial","author":"Liu","year":"2025"},{"key":"10.1016\/j.trecan.2026.09.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-03128","article-title":"Efficacy and tolerability of zenocutuzumab in advanced NRG1 fusion-positive cholangiocarcinoma: results from the eNRGy phase II trial","author":"Cleary","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0255","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0260","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2212 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2025.43.5_suppl.663","article-title":"Datopotamab deruxtecan in locally advanced\/metastatic urothelial cancer: updated results from the phase 1 TROPION-PanTumor01 study","volume":"43","author":"Meric-Bernstam","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0270","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0275","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0280","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.001_bb0285","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0290","doi-asserted-by":"crossref","first-page":"711","DOI":"10.21037\/tlcr-21-981","article-title":"Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer","volume":"11","author":"Low","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.001_bb0295","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.22.02833","article-title":"Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis","volume":"41","author":"Subbiah","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0300","article-title":"Precision oncology: a global perspective on implementation and policy development","volume":"11","author":"Horgan","year":"2025","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2013 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards \u2013 current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0315","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1038\/s41467-021-26019-y","article-title":"Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial","volume":"12","author":"Clark","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.001_bb0320","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0325","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.09.001_bb0330","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:25:51Z","timestamp":1791501951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326002128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"alternative-id":["S2405803326002128"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision before incision: neoadjuvant tumor-agnostic therapies","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}